Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral filed its Q3 FY26 investor presentation (quarter ended Dec 31, 2025) with BSE. Q3 FY26 revenue from operations rose 20.3% year-on-year to INR 208.6 mn, driven by strong growth in injectables and orals segments. Profit after tax jumped 37.8% YoY to INR 26.2 mn, with EBITDA margin expanding from 16.2% to 18.4% YoY. For the nine-month period, revenue grew a more modest 4.5% YoY to INR 542.5 mn, with PAT up just 1.3% at INR 59.9 mn. Exports continue to dominate at around 77% of revenue, with Middle East & Africa (46.7%) and Latin America (28.8%) as key markets. The company highlighted long-term growth drivers including product portfolio expansion, new geographies, and strategic partnerships such as its Prague JV.
The sharp Q3 acceleration in revenue and profits, along with healthy margin expansion, signals improving business momentum and operational leverage. However, the muted 9M FY26 growth indicates the Q3 surge may partly reflect one-off factors or a low base, warranting close tracking of the next quarter for confirmation of a sustained trend.